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In vitro, the ratio of single- to double-strand DNA breaks (DSB) and their absolute values determine the cell death pathway. The
consequences of the generation of various numbers of DSB generated in vivo in tumour cells have been analysed in two different
experimental tumour models. Synchronisation of DSB generation and control of their number have been achieved using different
doses of bleomycin (BLM) and tumour cell permeabilisation by means of locally delivered electric pulses. According to BLM dose,
different cell death pathways are observed. At a low therapeutic dose, a mitotic cell death pathway is detected. It is characterised by
the appearance of ‘atypical mitosis’, TUNEL and caspase-3 positive, 24h after the treatment, and later by the presence of typical
apoptotic figures, mainly TUNEL positive but caspase-3 negative. Caspase-3 is thus an early marker of apoptosis. Mitotic cell death is
also followed by lymphocytic infiltration reaction. At high doses of BLM, pseudoapoptosis is detected within a few minutes after the
treatment. These cell death pathways are discussed as a function of the number of DSB generated, by comparison with previous
results obtained in vitro using BLM or ionising radiation.
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Cell death following exposure to toxic agents can occur through
several routes, including apoptosis, extended or permanent cell
cycle arrest, necrosis and ‘mitotic catastrophe’. These various types
of cell death display different morphological changes and
biochemical characteristics. Such variations can result from
differences between cell types and the mechanisms by which cell
death is triggered.
At the cellular level, necrosis is characterised by an increased
plasma membrane permeability, cell swelling, a decline in protein
synthesis and autolysis (Wyllie et al, 1980; Schwartz and Osborne,
1993). It can be observed in solid tumours of mice treated with
arsenic trioxide (Lew et al, 1999).
Apoptotic cell death plays a major role in the regulation of cell
growth in multicellular organisms. It constitutes a systematic
means of cell suicide during normal embryonic development and
morphogenesis (von Wangenheim and Peterson, 1998), aging
(Monti et al, 1992) or in response to pathogenic infections and
other irreparable cell damage. Induction of apoptosis by anticancer
drugs has been demonstrated using, for example, paclitaxel
(Milross et al, 1996) or cisplatin (Trimmer and Essigmann,
1999). Recently, after cell treatment with ionising radiation, a
‘premitotic’ and a ‘postmitotic’ apoptosis could be distinguished as
a function of the morphological features of the treated cells
(Shinomiya et al, 2000). Apoptosis requires the activation of
proteases and endonucleases (Wyllie et al, 1984; Anderson et al,
1997). However, Tounekti et al (1993) showed that, in vitro, cell
uptake of large quantities of BLM, a nonpermeant drug that
generates double-strand DNA breaks (DSB), results in the very
rapid generation of the apoptotic morphological changes, as well
as in a DNA degradation similar to that observed in usual
apoptosis. This evolution was termed pseudoapoptosis (Tounekti
et al, 1993) because it is caused by the DSB generated by the
bleomycin (BLM) and does not require induction of proteases nor
endonucleases involved in typical apoptosis: BLM itself acts as a
microendonuclease (Tounekti et al, 1995).
In vitro, mitotic cell death is a slow process in which cell
metabolism remains functional for a period equivalent to more
than two cell cycles, the cell death being noticeable only after the
passage of the cell through one or more consecutive mitoses
(Chang and Little, 1991; Radford, 1991). These mitoses are,
nevertheless, aberrant and do not result in the formation of two
daughter cells (Dewey et al, 1970; Joshi et al, 1982). This results in
the generation of small abortive colonies by otherwise clonogenic
cells. Mitotic cell death can be initiated by the generation of a few
unrepaired DSB like those generated by small doses of ionising
radiation or the internalisation of low amounts of radiomimetic
drugs like BLM (Tounekti et al, 1993, 2001; Yanagihara et al,
1995).
Thus, in vitro, the number of DSB seems to determine the cell
death pathway. Single-strand DNA breaks (SSB) in very large
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Jonathan et al, 1999). We also reported that not only the absolute
numbers of DSB or SSB but also their ratio determine cell death
pathway: true apoptosis, pseudoapoptosis or mitotic cell death
(Tounekti et al, 2001).
On these basis, we decided to perform a systematic analysis of
the consequences of the generation of different numbers of DSB in
tumour cells in vivo. Control of DSB number, as well as
synchronisation of the DSB generation was achieved using
different doses of BLM and cell permeabilisation by means of
locally delivered electric pulses (EPs). Indeed, (a) external electric
fields generate changes in the transmembrane voltage and, under
appropriate conditions, provoke the transient and reversible
permeabilisation of the cells, in vitro as well as in vivo and
(b) BLM molecules do not diffuse through the plasma membrane
and they enter only at the time of the cell electropermeabilisation,
in amounts proportional to the external concentration at the
moment of EP. Moreover, permeabilising EP can be applied locally
in vivo on tumour nodules: the huge increase in the antitumour
effectiveness of BLM achieved by the increase in BLM uptake is the
basis of electrochemotherapy (ECT), a new way to treat solid
tumours that is already under clinical evaluation (Domenge et al,
1996; Mir et al, 1998; Gehl and Geertsen, 2000; Rodriguez-Cuevas
et al, 2001; Rols et al, 2002). Therefore, it seemed possible to study
in vivo the cell death pathway caused by different amounts of DSB
using these experimental conditions. Indeed, in ECT, as performed
in our preclinical and clinical studies, EPs alone are not toxic and
the toxicity observed is actually the toxicity caused by the
facilitated uptake of BLM.
MATERIALS AND METHODS
Tumour cells culture and tumour production
The LPB cell line, a methylcholanthrene-induced C57Bl/6 mouse
sarcoma cell line (Belehradek et al, 1972), and the B16 F0
melanoma cells (ATCC CRL 6322) were cultured using classical
procedures and minimum essential medium culture medium
(Gibco BRL, Cergy-Pontoise, France) supplemented with
100Uml
 1 penicillin, 100mgml
 1 streptomycin (Sarbach, France)
and 8% fetal calf serum (Gibco). These two cell lines had been
previously used in the laboratory in preclinical trials of the ECT
(Mir et al, 1991, 1992; Sersa et al, 1994) as well as for analysing in
vivo cell electrofusion (Mekid and Mir, 2000). C57Bl/6 female mice,
6–8 weeks old, were inoculated subcutaneously in the left flank
with 1 10
6 to 1.2 10
6 syngeneic LPB cells or B16 cells,
producing tumours 6–7mm of diameter 9 days later. Mice were
anaesthetised using a mixture of xylazine 12.5mgkg
 1 (Bayer
Pharma, Puteaux, France) and ketamine 125mgkg
 1 (Parke Davis,
Courbevoie, France). Animals were housed and handled according
to the recommended guidelines (Workman et al, 1998). They were
humanely killed by CO2 inhalation.
Tumour treatment
Bleomycin (Roger Bellon, Neuilly, France) was dissolved in sterile
0.9%. NaCl, aliquoted and stored at  201C. At 4min before EP
delivery, BLM was injected in the retro-orbitary sinus at a dose of
either 10mg, 100mg or 1mg in 100ml NaCl, per mouse,
(approximately 0.5, 5 or 50mgkg
 1).
Tumour electropermeabilisation was performed as previously
described (Mir et al, 1991). Stainless-steel external plate electrodes
were placed on both sides of the protruding tumour, contact with
skin was ensured by electrocardiography paste. Square-wave EPs
(eight pulses of 100ms delivered at a frequency of 1Hz) were
generated by a PS15 electropulsator (Jouan, St Herblain, France)
and controlled through a VC-6025 oscilloscope (Hitachi, Japan).
For 1350Vcm
 1 pulses, 800V was applied between two parallel
electrodes 10mm large and 6mm apart. It was already known that
these electrical parameters allow for the in vivo reversible
electropermeabilisation of almost of cells in the LPB and B16F0
tumours since the administration of these EPs alone, without BLM,
(like the administration of the BLM alone, with no EP), caused no
statistically significant tumour growth delay (with respect to the
control untreated tumours), while the concomitant administration
of these EPs with BLM resulted in the achievement of complete
regressions and even of cures (Mir et al, 1991, 1992, 1996; Sersa
et al, 1994; Mekid and Mir, 2000). Then, mice were returned to
their cages for different periods (between 1 and 100h) and killed to
remove the tumours for histological processing. Three mice (i.e.
three independent tumours) were used for each experimental
condition.
Histological procedures
Tumours were fixed in AFA (75% ethanol, 5% acetic acid and 2%
of formaldehyde 40%) for 24h, dehydrated and included in
paraffin. Slices of 5mm were prepared using a Reichert-Jung 2030
microtome (Microm-Zeiss, Jena, Germany). Then slides were
rehydrated and stained with HES (hemalun, 0.2%; eosin, 0.3%,
saffron, 5%). Alternatively, rehydrated slides were washed in
phosphate-buffered saline (PBS; 50mM Na2HPO4,5 0m M NaH2PO4
and 200mM NaCl, pH 7.4) and stained with 3mM propidium iodide
(PI) (Sigma, La Verpillie `re, France).
Immunohistochemical cell death determinations
Apoptosis-specific staining (based on free DSB extremities
labelling) was performed using the In-situ-Cell-Detection Kit,
either alkaline phosphatase (AP) or fluorescein (Roche Molecular
Biochemical, France). Deparaffinated slides were washed in PBS,
digested with 20mgml
 1 Proteinase K (Sigma) and processed
according to the manufacturer’s instructions. Briefly, free 30-OH
termini were labelled with fluorescein isothiocyanate (FITC)-
labelled deoxyuridine using the terminal transferase enzyme and
detected either by fluorescence microscopy or with an AP-coupled
anti-fluorescein antibody, and the subsequent incubation with fast
red substrate.
The implication of a caspase-dependent cell death pathway was
studied using an anti-activated caspase-3 antibody (Pharmingen,
San Diego, USA) (Hadjiloucas et al, 2001). Slices were depar-
affinated, treated in a microwave oven and incubated overnight at
41C in the presence of the 1:500 diluted antibody. The positive
cells were revealed using an appropriate Power Vision Detection
AP System (ImmunoVision Technologies, Dalycity, CA, USA) and
analysed using a Leica DMRB light microscope (Leitz, Wetzlar,
Germany).
Electron microscopy
The treated tumours were fixed with phosphate-buffered glutar-
aldehyde (Ladd Research Industries, England), postfixed with
osmium tetroxide (Prolabo, France) and then dehydrated,
processed, sliced and observed under a Zeiss 902 electron
microscope.
Microscopic slides examination
Slides were examined under a Leica DMRB microscope equipped
with an automatic photographic device. For fluorescence micro-
scopy, the filter set for rhodamine detection was used to observe
the PI-stained slices and the filter set for FITC detection to observe
the apoptotic cells stained with the In-situ-Cell-Detection Fluor-
escein Kit.
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from each mouse, three HES-stained tumour slides were prepared.
In all the cases, the entire slide was examined to detect all the types
of cell patterns generated under each experimental condition. To
determine the percentages of each cell pattern, all the cells from
four randomly chosen fields of non-necrotic areas of each of the
three slices prepared from each tumour were counted. The
percentages of each cell pattern were calculated with respect to
the total number of cells counted. On the average, 1500 cells were
counted for each experimental condition.
Statistical analysis
All data are presented as means and standard deviations. Statistical
analysis of the significance of the difference between the controls
and the groups treated under the various experimental conditions
was performed using Student’s t-test.
RESULTS
Based on their morphology, tumour cells were classified into four
categories: (a) cells with normal morphology and size, (b) atypical
cells (see below), (c) apoptotic cells showing classical DNA
condensation and (d) typical mitotic cells. The percentages of
cells in each category were determined at various times after
tumour exposure to EP in BLM-injected mice (i.e. after ECT).
Morphological estimation of apoptosis was based on cell
characteristics, such as marked condensation and marginalisation
of the chromatin or formation of apoptotic bodies. Atypical cells
were the ones showing extended and intense pycnosis, where it was
impossible to distinguish between the nucleus and cytoplasm.
Under some conditions, further described, cells with normal
morphology but larger than those found in untreated tumours
were also observed. Even though their apparent diameter could
reach twice the apparent diameter of the normal cells, they were
still counted as cells with normal morphology.
Histological characteristics of the untreated tumours
As revealed by HES staining, LPB fibrosarcoma was a tissue in
which many mitosis were detectable (Figure 1A, B). Cells were
densely packed and the membrane separating each individual cell
was not always distinguishable. In the absolute control 570.3% of
cells were in mitosis (Figure 2I), 2.770.1% in the EP alone control
and 370.2% in the BLM alone control (the data concerning the EP
alone control and the BLM alone control are not shown in the
figures; they were obtained on tumours removed and fixed 5h after
the respective treatment). The percentages of typical apoptotic
figures (Figure 1B) were 3.170.9% in the absolute control (Figure
2II), 2.770.7% in the EP and 2.570.5% in the BLM controls.
Atypical figures (Figure 1A) were regularly found in all LPB
control tumours: 4.371.8% in the absolute control (Figure 2III),
5.570.7% in the EP and 570.7% in the BLM controls.
In the B16 tumours, the membrane limiting each individual cell
was clearly visible (Figure 1C, D). The nuclei in the untreated
control tumours displayed a relatively regular size and were
usually located in the centre of the tumour cells. In absolute
control, 2.370.1% of the cells were in mitosis (Figures 1C and 2I),
4.070.1% in the EP alone and 1.370.1% in the BLM alone
controls. The percentages of typical apoptotic figures were
2.070.2% in the absolute control (Figure 2II), 3.570.3% in the
EP and 2.670.5% in the BLM controls. Atypical figures (Figure 1D)
were regularly found also in all the B16F0 control tumours
(2.470.1% in the absolute control (Figure 2III), 4.070.6% in the
EP and 7.070.7% in the BLM controls).
No immune cell infiltrated the LPB tumour tissue in the absence
of treatment. Some lymphocytes were detected at the periphery of
the tumour only. In the B16 melanoma, spontaneous necrosis areas
were found even in small-untreated tumours. In these areas,
immune cells could be easily observed (data not shown).
Changes in the fraction of cells in mitosis after in vivo
exposure to BLM and EP
Using a high dose of BLM (1mg per mouse) After the treatment, a
rapid decrease in the fraction of cells in mitosis was observed in
both tumours, and after 3h mitoses became almost undetectable
(Figure 2IA). At 5min after the treatment of LPB or B16F0, the
percentage of mitosis decreased to approximately 40–45% of
controls. These percentages continued to decline significantly in
the tumours at 1h, and later, after the ECT (Figure 2IA).
Interestingly, the existence of abnormal mitosis was detected in
HES-stained slices 10–20min after the treatment. At 30min, all the
mitoses still visible displayed aberrant figures. No mitosis was
observed thereafter.
Using a low dose of BLM (10mg per mouse) A similar drastic
reduction of the fraction of cells in mitosis was observed in both
the tumours (Figure 2IB). The percentage of mitosis in LPB and
B16F0 was found to be reduced at 5h after the treatment and
remained at this low value until 100h in the case of the LPB
tumour. In the case of B16F0, the decrease was smaller at 5h than
the decrease observed in LPB, and some cells in mitosis were still
detected at 30h. However, these percentages were lower than in
untreated controls (Figure 2IB).
Changes in the fraction of apoptotic cells
Using 1mg BLM per mouse In the LPB tumours, cell morphology
started to change in certain areas of the tumours very shortly after
the EP delivery. As revealed by the HES staining, as soon as 5min
after the treatment, 20% of the observed nuclei displayed
condensation of chromatin that evoked apoptosis. At 10min, the
Figure 1 Histological characteristics of the untreated murine fibrosarco-
ma tumour LPB (A and B) and murine melanoma tumour B16F0 (C and
D). Small arrows: mitotic cells; large arrows: apoptotic cells; arrowheads:
atypical cells.
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control tumours. A maximum of 34.576.3% of nuclei with
condensed and margined chromatin was reached at 30min (Figure
2IIA).
Changes were more pronounced in certain areas of the tumours
slices where all the cells displayed marked condensation of the
chromatin, and sometimes already the appearance of apoptotic
bodies (Figure 3A, C). In order to clearly visualise the conden-
sation and marginalisation of chromatin in nuclei and to
confirm these data, we also stained some slices with PI (data not
shown).
In the B16F0 tumours treated under the same conditions, a
massive percentage of apoptotic cells were also observed in some
areas of the tumour (Figure 3B, D). However, the increase in
apoptotic cells was more progressive (Figure 2IIA) since a highly
significant five-fold increase was observed only at 20min
(11.372.3%). For both LPB and B16F0 tumours, a decrease in
the fraction of the apoptotic cells was observed at 1h after the
treatment, followed, respectively at 2 and at 3h, by an ulterior
increase (Figure 2IIA).
Using 10mg BLM per mouse In the presence of a low amount of
BLM, it was possible to subdivide the evolution of the fraction of
apoptotic cells into two intervals (Figure 2IIB), before and after
25h after the ECT. In the interval of 0–25h, the percentage of
apoptotic cells was similar to that of the control tumours (around
2%), although a significant four-fold increase in apoptotic cells was
observed in the B16F0 population at 10h. In both tumours from
25h until 100h, the percentage of apoptotic cells progressively
increased up to a maximum observed at 50h (respectively 30.1%
for the LPB and 25.6% for the B16F0 tumours) (Figure 2IIB and
3E, F).
In the B16F0 melanoma tissue, it was necessary to distinguish
between the areas with individual cells and those with large
polykaryotic cells resulting from the in vivo electrofusion of B16F0
cells (Mekid and Mir, 2000). In the areas containing individual
unfused cells, no change in the percentage of apoptotic cells was
found at any time after the treatment between the treated and
controls. On the contrary, in the areas displaying fused cells, the
percentage of apoptotic cells increased significantly from 25h after
the treatment until 100h. At 50h, 92.8% of the whole of the
apoptotic nuclei were found in the fused cells, and 96.4% of
the nuclei in the fused cells were apoptotic. (data not shown in the
figure).
Thus, our results show that apoptotic cells can be found either
very rapidly after the treatment in the presence of a high amount of
BLM or after more than 25h in the presence of a low amount of
BLM.
Changes in the fraction of atypical cells
Using 1mg BLM per mouse A net increase in the fraction of
atypical cells (two-fold with respect to the untreated tumours) was
found in LPB fibrosarcoma 5min after the treatment. At 10min,
the increase was approximately four times. This increase persisted
at 3h and later on (at 5, 8 and 24h) (Figure 2IIIA). Contrary to LPB
fibrosarcoma, the percentage of atypical cells became larger (seven
to nine times higher) than that observed in untreated control
tumours only at 2h and then at 8 and 24h, while in the interval
between 0 and 1h, values were close to that of control B16F0
tumours (Figure 2IIIA).
Using 10mg BLM per mouse The rate of atypical cells in LPB
tumours was slightly increased at all times except at 100h. A
significant increase was found at early times (up to 5h) as well as
at later times (30–50h). This evolution was very different
compared to the changes in apoptotic cells in the same
fibrosarcoma (Figure 2IIB, IIIB). Contrary to LPB fibrosarcoma,
the trend of the changes in the percentage of atypical cells in B16F0
tumours was not clear. Variations were observed from each time
point to the next one. Variations with respect to control values
never exceeded three times (Figure 2IIIB).
Figure 2 Kinetics of the fraction of (I) mitotic cells, (II) apoptotic cells and (III) atypical cells in LPB and B16F0 tumours after ECT using 1mg BLM (panels
A) or 10mg BLM (panels B). Statistical analysis: all groups were compared to the respective controls by means of Student’s t-test. All groups were significantly
different from the controls (at least Po0.05) except in panels IIA LPB (at 1 and 8h), IIA B16F0 (at 5min and 1h), IIB LPB (before 20h), IIB B16F0 before
25h, IIIA B16F0 (at 5min and 1h), IIIA LPB (20min, 1h and 2h), IIIB B16F0 at 50h and IIIB LPB at 15, 20, 25 and after 70h.
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Changes in tumour cell size At the high dose, no change in cell
size was observed: both the atypical and the apoptotic nuclear
changes were detected in cells displaying the same apparent
diameter than in the untreated tumours. At the low dose, for the
first 25h following the EP, the cells showing a normal nucleus
became progressively larger than in untreated tumours. At the end
of this period, the apparent diameter of the nuclei could be twice as
large as that of the normal cells. This evolution was observed in
both LPB and B16F0 tumours treated using 10mg BLM (data not
shown). As a consequence, atypical cells displayed an apparent
diameter larger than that of the control tumour cells, while
apoptotic cells displayed a diameter lower than that of the atypical
cells but still similar to that of the cells in control tumours.
Changes in immune cell distribution After ECT using 1mg BLM,
no change in the distribution of the immune cells infiltrate was
observed. Using 10mg BLM, it was possible to detect a large
infiltration of the LPB tumours by lymphocytes from 25h after the
EP delivery. At longer times, such as 50 or 70h, a large number of
infiltrating lymphocytes were present in all the parts of the LPB
tumours, but with a higher density where a large fraction of
apoptotic cells was also present. In the case of the B16F0 tumours,
in which lymphocytes were already detectable in the spontaneous
necrosis area controls, no major change could be noticed at any
time.
Electron microscopy
Slices of B16F0 tumours treated with 1mg of BLM and removed at
10min, 15min and 1h were analysed to verify that the rapid
change in chromatin morphology was similar to that observed
when apoptosis occurred spontaneously or when it was induced by
other known agents. Changes in the nuclei were actually typical of
apoptotic cells (Figure 4A, B): the chromatin was condensed at the
limit of the nucleus, forming clumps pressed against the nuclear
envelope, and the cytoplasm was dense. Moreover, at 1h,
mitochondria displayed autolytic changes (data not shown).
We also checked whether the atypical cells detected under light
microscopy showed ultrastructural modifications similar to or
different from those of the apoptotic cells. The chromatin
fragments that are observed in atypical cells can be surrounded
by a double membrane (Figure 4C) as already found by Dini et al
(1996), who treated the cells using H2O2 and described the images
seen in the atypical cells as a result of perturbations in the
condensation of the mitotic chromosomes.
Figure 3 Histological changes observed in tumours removed 30min
after ECT using 1mg BLM (A–D) and in tumours removed 50h after ECT
using 10mg BLM (E and F); (A, C and E): LPB tumours; (B, D and F):
B16F0 tumours.
Figure 4 Electron microscopy images of LPB tumours treated by ECT:
(A) untreated control fibrosarcoma; (B) typical apoptotic cell observed in
tumours removed 30min after ECT using 1mg BLM; (C) atypical cell
observed in tumours removed 25h after ECT using 10mg BLM, the arrow
indicating the double membrane;  17500.
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TUNEL-specific assay for apoptotic cells Nuclei presenting
chromatin condensation as well as atypical cells were found
positive with the TUNEL assay demonstrating that chromatin was
fragmented in these cells (Figure 5). The TUNEL staining was also
applied to LPB cells electropermeabilised in vitro in the presence
of high external concentrations of BLM (from 10 to 66mM) that
resulted in pseudoapoptosis. A progressive increase in the number
of positive cells and in the intensity of the staining was found with
increasing external concentrations of BLM (data not shown).
Therefore, the TUNEL assay was able to label both the real
apoptotic cells and the pseudoapoptotic cells generated by the
introduction, in vivo, of large amounts of BLM into the tumour
cells. At a low dose of BLM, cells were TUNEL negative for at least
15h suggesting strongly that the number of DSB directly generated
by the low BLM dose was very low.
Caspase-3 staining In the absence of treatment, a large number of
the atypical cells found in the LPB or B16 tumours were caspase-3
positive, while only a few of the apoptotic cells were caspase-3
positive.
After ECT of LPB tumours using 1mg BLM, a large number of
cells very rapidly displayed apoptotic characteristics (Figure 3),
whereas the anticaspase-3 staining was restrained only to a very
few apoptotic or atypical cells, confirming the pseudoapoptotic
evolution suggested by the morphological analysis. At 5h, when
the percentage of LPB atypical cells was very high, the number of
stained cells was also high, involving a large fraction of these
atypical cells (Figure 6).
After ECT with 10mg of BLM, caspase-3 staining was observed
only after 25h in most of the atypical cells, as well as a few of the
apoptotic cells. All the large cells were caspase-3 positive and their
staining was more intense than the staining observed after a high
dose of BLM or in untreated controls. In additional experiments
(data not shown), slides of tumours treated with an intermediary
dose of BLM (100mg per injection) were also examined. Their
histological analysis revealed a large number of atypical cells that
were mainly caspase-3 positive, even though, again, all the atypical
or condensed cells were not stained.
DISCUSSION
Two important findings emerged from these results. First, ECT
with BLM immediately induces in vivo a large decrease of the
number of cells in mitosis and secondly, BLM induces two distinct
types of tumour cell death, as a function of the BLM dose injected
before the ECT. These observations can be related to previous data
using cells in culture. First, in vitro, no mitosis is detectable after
cell electropermeabilisation in the presence of BLM: cells
accumulate in G2/M if low concentrations of BLM are used, while
pseudoapoptotic figures are generated in the presence of large
BLM concentrations. Secondly, in vitro as well (Tounekti et al,
1993), after cell electropermeabilisation in the presence of different
doses of BLM, we observed two very different groups of
morphological features that, as further discussed here, allow to
conclude that, both in vitro and in vivo, tumour cells can die either
through a mitotic cell death process at low BLM doses or by
pseudoapoptosis at high doses. This BLM-dose-dependent cell
death is present in the two tumours studied, which were chosen for
this study because both tumours grow in the C57Bl/6 mice,
keeping homogeneous the host reactions, and because the same
pulse parameters are necessary to achieve the electropermeabilisa-
tion of almost all the cells in the tumour. Interestingly, these two
tumours differ by their histological origins, spontaneous tendency
to necrose and spontaneous lymphocytic infiltrate. Moreover, they
respond differently to the EP (Mekid and Mir, 2000).
Evolution of the number of ‘apoptotic figures’ and ‘atypical
figures’, and origin of these figures
Besides the decrease in the number of mitotic figures, our new in
vivo data show that, at low and high BLM doses, there is a large
increase of two types of figures that we classified as ‘apoptotic
figures’ and ‘atypical figures’ (already present in low percentages
in the untreated tumours). For the LPB and B16F0 apoptotic cells,
similar changes were observed, except that, at the high BLM dose,
the increase in the number of apoptotic cells was detected earlier in
the LPB than in the B16F0 tumours. The atypical figures were
previously analysed after in vitro cell treatment by H2O2 (Shacter
et al, 2000): according to these authors, atypical figures correspond
Figure 5 Immunohistochemical detection of DNA fragmentation in tumour cells. Fluorescein detection (A–C); alkaline phosphatase detection (D–F);
(A–C): LPB fibrosarcoma; (D–F): B16F0 melanoma; (A and D): stained untreated controls; (B and E): staining of tumours removed 30min after ECT using
1mg BLM; (C and F): staining of tumours removed 50h after ECT using 10mg BLM.
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cells showing cytoplasmic swelling and mild pycnosis of the
nucleus. On the one hand, after ECT, at the low BLM dose,
the appearance kinetics of the atypical figures were similar for both
the tumour types. They appeared after a long period (25h), which
is, nevertheless, much shorter than the in vivo generation time
(Sersa et al, 1994). Since in the mean time the cells had become
much larger, these atypical figures were mainly large cells. They
represent a phase in the process of mitotic cell death, and as
discussed below could be either a step before the appearance of the
classical apoptotic figures or another step of the cells dying
through the mitotic cell death pathway. On the other hand, at the
high BLM dose, atypical figures appeared rapidly (in a few minutes
in the LPB tumours, and at 2h and then at 8h in B16F0 tumours).
Cells had no time to enlarge and did not differ in size from the
untreated control cells. Thus, the origin of the atypical cells could
be different, depending on the BLM dose.
The analysis of the atypical and the apoptotic cells shows that
both are TUNEL positive. However, while most of the atypical cells
were caspase-3 positive, most of the apoptotic cells were not. These
two types of figures could perhaps correspond to two different
stages in a common apoptotic pathway (Hadjiloucas et al, 2001) or
to two different apoptotic cell death pathways, one caspase-3
dependent and one not (Tauchi and Sawada, 1994; Yanagihara et al,
1995; Kolenko et al, 2000). These two pathways could result from
differences in the cell cycle position of the cells at the time of their
electropermeabilisation and, therefore, at the time of the DSB
generation, or from a different number of BLM molecules
internalised (thus of a different number of DSB). It is interesting
to note that using low BLM doses, the number of DSB is low just
after the ECT and cells remain negative to the TUNEL assay for
several hours (the DSB directly generated by BLM are actually
recognised by the TUNEL assay, as reported in the Results
section). However, atypical cells (as well as apoptotic cells) are
TUNEL positive, indicating that a cell process generating DSB
apoptosis has been actually induced after the DNA damage
provoked by the low amount of the BLM.
In vivo BLM causes mitotic cell death or pseudoapoptosis
Our data show that there are two cell death types observed after
ECT, which can be related to the action of the BLM entering the
cells in vivo in different amounts and thus to the generation of
different numbers of DSB. The results can be compared to those
found on cells in culture where it was easy to test a large number of
different BLM concentrations. In vivo it is not easy to acquire the
amount of data as it is in vitro, and only two different amounts of
BLM (differing 100 times) injected to the mice were analysed in
detail. An intermediary concentration, 100mg per mouse, was
also tested (data not shown) and intermediary results were
found in the time points examined confirming the dependence,
discussed below, of the changes observed on the amount of
injected BLM.
In vitro, in the presence of 10 or 100mM BLM (high doses), cells
displayed a pseudoapoptotic evolution: all the apoptosis morpho-
logical and biochemical characteristics (Kerr and Searle, 1972)
could be found, shortly after the ECT (as reported in the
introductory section). In fact, the speed at which these changes
were obtained was dependent on the BLM external concentration:
the higher that concentration, and therefore the higher the amount
of BLM internalised into the cells (Poddevin et al, 1991), the faster
the changes observed (Tounekti et al, 1995). Thus in vivo, at the
high BLM dose, the large numbers of rapidly appearing apoptotic
figures could be the result of a pseudoapoptotic process. It is also
interesting to note that, with the high BLM dose, the large amounts
of apoptotic figures here reported at 30min after ECT were, in fact,
localised in defined areas of the tumours, where almost all the cells
in that area displayed chromatin condensation. These areas were
almost undetectable at 1h, may be because the apoptotic residues
had been phagocytosed by the neighbouring live cells. At 2 or 3h,
large areas comprising almost exclusively apoptotic figures were
found again. This observation can be explained taken into account
that (i) in vitro the speed at which chromatin condensation is
detected in electropermeabilised cells exposed to high external
BLM concentrations is dependent on the external concentration,
(ii) the supply of BLM in the tumour is not homogeneous and very
much related to the tumour vasculature and (iii) that the electric
field distribution and thus cell electropermeabilisation is not
totally homogeneous within the whole tumour. Thus, like in vitro,
the larger the amount of BLM available and internalised, the faster
the appearance of the apoptotic figures, suggesting that in vivo as
well, a ‘pseudoapoptosis’ is the mechanism of cell death caused by
the rapid uptake of large amounts of BLM.
For the low doses of BLM, the in vivo and in vitro evolutions are
not identical. Indeed, in vitro, in the presence of 10 or 100nM BLM
(low doses), the electropermeabilised cells died slowly through a
process reminiscent of the mitotic cell death described after the in
vitro treatment of cells by ionising radiation (Chang and Little,
1991; Radford, 1991). No mitosis was detectable for a period
equivalent to a cell cycle after the BLM internalisation, resulting in
the accumulation of the cells in G2. This blockage was followed by
an abnormal mitosis that resulted in the appearance of only one,
large, often binucleated cell that could still complete a second
entire cell cycle (Tounekti et al, 1993). A second mitosis could
Figure 6 Immunohistochemical detection of activated caspase-3: (A and
B): LPB tumour removed 5h after ECT using 1mg BLM; (C) LPB tumour
removed 50h after ECT using 10mg BLM.
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ssometimes be observed. Karyotypes were highly modified
(Tounekti et al, 1993). Cell death, that is, the cessation of cell
metabolism, and the disappearance of cell structure occurred by
processes that could not be described. Indeed, in vitro, the
experimental synchronisation of the mitotic cell death triggering
obtained by the cell electropermeabilisation, which allowed the
study of the initial steps of this pathway, could not be maintained
to describe its final steps. We could not detect the appearance of
the oligonucleosomal ladder, but this does not mean that no
apoptosis could occur. In fact, we supposed that cells were dying
because of necrosis (i.e. that cells swelled, lysed and released their
content into the extracellular medium).
In vivo, at low BLM doses, cells present an evolution that, at the
beginning, is reminiscent of the in vitro observations (transient
mitosis disappearance). However, in vivo, the end point of this
evolution seems to be typical and/or ‘atypical’ apoptosis. It cannot
be totally excluded that the atypical cells could be the result of an
‘atypical apoptosis’. However, in agreement with the conclusions
of Hadjiloucas et al (2001), our results suggest that in vivo the
atypical cells, which are caspase-3 positive, could be an
intermediary step between the still alive treated cells and the
apoptotic dead cells. Caspase-3 positive staining, which allows to
distinguish easily the atypical cells generated during the mitotic
cell death process, is thus an interesting early marker of apoptosis,
as already suggested by Hadjiloucas et al (2001).
There is still another possibility to explain the differences
between the in vitro and in vivo results using small doses of BLM.
Indeed, in the B16 tumours, no major change in the immune
system infiltration was detected, while in the LPB tumours, after
ECT with 10mg BLM, a massive infiltration of immune system cells
was observed at the time points where a large fraction of apoptotic
cells was also detectable (25–100h after the treatment). Interest-
ingly, the percentage of apoptotic cells in LPB tumours was slightly
higher than that in the B16F0 tumours. Of course, this could result
from different kinetics in the generation and disappearance of the
apoptotic cells in both tumours, but it cannot be excluded that the
infiltrating immune system cells present in the LPB tumours at
these time points could contribute to the generation of apoptotic
cells. As a matter of fact, it is known that LPB cells are
immunogeneic (Belehradek et al, 1972) while the B16F0 are not.
In parallel, it must be noted that a large fraction (up to 60%) of
LPB tumours can be cured after one single ECT session using 10mg
of BLM per mice (Mir et al, 1992) while, using exactly the same
protocol, only 16% of the B16F0 tumours could be cured (Sersa
et al, 1995). Moreover, the observation (Figure 2B) of the presence
of a small fraction of mitotic B16F0 cells in the treated tumours
(almost not detected in the LPB tumours) from 30h on after
the ECT is quite in line with the results of tumour cure. Thus,
after the injection of a low BLM amount, the apoptosis detected
in B16F0 tumours reinforces the suggestion that, in vivo, the
final outcome of mitotic cell death is an apoptosis, in agree-
ment with previous in vitro studies using ionising radiation
(Tauchi and Sawada, 1994; Yanagihara et al, 1995). Simulta-
neously, our results also suggest that in LPB tumours the high
fraction of apoptotic cells could result from the direct outcome of
the treatment and the concomitant cytotoxic activity of the
immune system.
In summary, using the high BLM dose, a pseudoapoptotic
evolution of the tumour cells was found, reminiscent of the
observation performed in vitro on cells electropermeabilised in the
presence of high external BLM concentrations. Using the low dose,
a cell death pathway like the one observed after tumour treatment
by ionising irradiation (mitotic cell death) was observed shortly
after the treatment. This cell death pathway ended through a real
apoptotic process. The atypical caspase-3 positive figures are an
intermediary step in this process. Thus, antiactivated caspase-3
staining is an early marker of apoptosis. Moreover, the difference
in the results obtained in vivo with the high and low amounts of
BLM can actually be interpreted, as in vitro, as the direct
consequence of the number of BLM molecules internalised into
the cells and, therefore, as the result of the number of DSB
generated in these cells.
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